Lewy Body Dementia

🔍 Three Things You Likely Didn’t Know About Lewy Body Dementia

1. Robin Williams had Lewy body dementia. After the actor’s death in 2014, his autopsy revealed widespread Lewy body pathology. His widow described a trajectory of depression, anxiety, paranoia, cognitive fluctuations, and movement changes in the months preceding his death — symptoms that had been attributed to Parkinson’s disease and depression during his life. The case brought unprecedented public awareness to LBD and illustrated how profoundly the disease can affect mood, behavior, and identity (Williams, 2016).

2. Patients with Lewy body dementia see people who aren’t there — in photographic detail. Unlike the voices heard in schizophrenia, LBD hallucinations are overwhelmingly visual: detailed figures of people, children, or animals, sometimes with describable clothing and facial features. Early on, patients often know these visions aren’t real — which makes the experience all the more surreal and distressing. At the same time, most antipsychotics can be dangerous in someone with LBD and require careful selection and application.

3. Lewy body dementia may announce itself decades before symptoms — through your dreams. REM sleep behavior disorder — physically acting out dreams, sometimes violently — is one of the strongest known predictors of Lewy body disease: a significant proportion of people with confirmed RBD eventually develop LBD or Parkinson’s, often 10–15 years after the sleep symptoms begin (Iranzo et al., 2013). The same protein deposits that cause dementia appear first in brainstem regions controlling dream paralysis, making RBD a potential window for early response and intervention.

---

📋 Overview

Lewy body dementia (LBD) is an umbrella term encompassing two related conditions: dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). Both share the same underlying pathology — the accumulation of alpha-synuclein protein into intracellular inclusions called Lewy bodies — but differ in the sequence and timing of cognitive and motor symptoms.

In DLB, cognitive symptoms appear first or alongside motor features; in PDD, the motor symptoms of Parkinson’s precede dementia by at least a year. Whether these represent distinct diseases or points on a spectrum remains debated, but the clinical challenges are similar.

The core clinical features of LBD can include:

• Fluctuating cognition — attention and alertness can change dramatically within hours. A patient may be lucid and engaged in the morning and profoundly confused by afternoon.
• Recurrent visual hallucinations — typically well-formed, detailed, and often featuring people or animals.
• Parkinsonism — rigidity, bradykinesia, and sometimes tremor, overlapping substantially with Parkinson’s disease.
• REM sleep behavior disorder (RBD) — the loss of normal muscle atonia during REM sleep, causing patients to physically act out their dreams, and sometimes fall out of bed or injure their sleeping partners

Additional features may include autonomic dysfunction (orthostatic hypotension, urinary incontinence, constipation), depression, apathy, anxiety, and exquisite sensitivity to antipsychotic medications.

---

🔀 Subtypes and Presentations

The two main clinical entities within LBD differ primarily in their temporal presentation:

• Dementia with Lewy bodies (DLB) — cognitive impairment is the presenting or early feature, with attention, executive function, and visuospatial abilities affected more prominently than memory in the early stages (a pattern that can help distinguish DLB from Alzheimer’s). Motor parkinsonism may emerge concurrently or later.
• Parkinson’s disease dementia (PDD) — dementia develops in the context of established Parkinson’s disease, typically after years of motor symptoms. Cognitive impairment in PDD tends to be characterized by slowed processing speed, executive dysfunction, and attentional deficits, with memory retrieval difficulties rather than the encoding failures seen in Alzheimer’s.

---

🩺 Diagnosis

Accurate diagnosis of LBD is critically important — more so, perhaps, than in any other form of dementia — because of its implications for medication safety. Key diagnostic elements include:

• Detailed clinical history with informant input — the temporal relationship between cognitive, motor, behavioral, and sleep symptoms is essential.
• Cognitive assessment — if indicated, neuropsychological testing typically reveals disproportionate impairment in attention, executive function, and visuospatial/visuoconstructional abilities relative to memory — a profile that differs from the early memory-dominant pattern of Alzheimer’s disease.
• Motor examination — assessment for parkinsonian features (rigidity, bradykinesia, tremor, gait disturbance).
• Sleep evaluation — a history of dream enactment behavior (RBD) is highly suggestive. Polysomnography may be used to confirm REM sleep without atonia.
• Neuroimaging — structural MRI may show relative preservation of medial temporal lobe structures (in contrast to the hippocampal atrophy typical of Alzheimer’s). Dopamine transporter (DaT) imaging demonstrating reduced dopaminergic uptake supports a DLB diagnosis and is now incorporated into diagnostic criteria. FDG-PET may show the characteristic “cingulate island sign.”
• Cardiac autonomic testing — cardiac MIBG scintigraphy showing reduced sympathetic innervation is a helpful biomarker for LBD, although not often used.
• Psychiatric differential diagnosis — LBD can mimic primary psychiatric disorders, particularly late-onset psychosis, delirium, and major depressive disorder. The visual hallucinations, in particular, may be initially attributed to a psychiatric condition rather than a neurodegenerative one.

Misdiagnosis of LBD as Alzheimer’s disease is common and consequential: medications often used in Alzheimer’s-associated agitation can be dangerous in LBD. Misdiagnosis as a primary psychotic disorder is equally hazardous for the same reason.

---

💊 Treatment Approach

The treatment of Lewy body dementia demands a uniquely cautious and knowledgeable approach, given the condition’s extreme medication sensitivities and the complex interplay between cognitive, motor, psychiatric, and autonomic symptoms.

Behavioral Interventions

Structured behavioral interventions and environmental modifications play a central role in LBD. Establishing consistent routines, optimizing lighting to reduce visual misperceptions, and ensuring adequate nighttime sleep can meaningfully reduce hallucinations, agitation, and confusion without medication. Acceptance-based approaches — helping families understand hallucinations as neurological phenomena rather than signs of “madness,” and helping patients relate to cognitive fluctuations with less distress can be helpful for assuaging concerns. They can also set the ground for value-driven activities that re-energize the family.

Medication and Neuromodulation

The pharmacological management of LBD is among the most nuanced in clinical psychiatry.

For cognitive symptoms, cholinesterase inhibitors are the first-line pharmacological approach and may be more effective in LBD than in Alzheimer’s disease — in part because the cholinergic deficit is particularly pronounced in Lewy body disorders. Improvements in attention, hallucinations, and behavioral symptoms have been well documented.

For visual hallucinations and psychosis, the conventional antipsychotic pharmacopeia is largely contraindicated. The neuroleptic sensitivity of LBD means that standard dopamine-blocking agents can trigger severe, sometimes irreversible, life threatening reactions. Management of psychosis in LBD requires agents that address psychotic symptoms while largely sparing the dopamine system — a narrow therapeutic window that demands specialized expertise.

For motor parkinsonism, dopaminergic therapy may be cautiously trialed, though the therapeutic window is narrower than in classical Parkinson’s disease because dopaminergic medications can exacerbate hallucinations and psychosis.

For REM sleep behavior disorder, safety measures (removing dangerous objects from the bedside, using bed rails, separating sleeping partners if necessary) are the first priority. Pharmacological options exist and can substantially reduce dream enactment episodes.

Depression, anxiety, and apathy require pharmacological approaches chosen with awareness of both the cholinergic and dopaminergic sensitivities inherent to LBD. Drug interactions and side effect profiles must be evaluated with particular care, and strategic deprescribing — removing medications that may be worsening cognition or motor function — is often as important as adding new ones.

Integrative and Lifestyle Approaches

Given the overlapping vulnerabilities in LBD — neuroinflammation, oxidative stress, cholinergic depletion, autonomic instability, and sleep fragmentation — targeted integrative interventions may play a meaningful supportive role. Optimizing sleep architecture, supporting autonomic regulation, and addressing nutritional factors relevant to synucleinopathy and neuroinflammation are areas where individualized strategies can complement conventional treatment. As always, the specifics matter and are best discussed in the context of a comprehensive evaluation rather than applied generically.

There is no algorithm that replaces careful clinical judgment informed by a thorough understanding of this condition.

---

🌱 Outlook

Lewy body dementia is progressive, and this reality must be acknowledged with honesty. However, the nihilism families sometimes encounter — “there is nothing we can do” — is not true. The psychiatric and behavioral symptoms of LBD are among the most treatable aspects of the disease when managed by a clinician with appropriate expertise. Hallucinations can be reduced or made less distressing. Sleep can be improved. Depression and anxiety can be treated.

The disease trajectory is variable — average survival from diagnosis ranges from 5 to 8 years although it is impossible to predict with exactness — and the quality of those years is profoundly influenced by whether treating clinicians understand the unique pharmacological sensitivities and psychiatric complexity of this condition.

---

🏥 How to Get Better

At our psychiatry practice, we have extensive experience in treating the psychiatric dimensions of Lewy body dementia and bring a thoughtful, evidence-based approach to managing them. At times, medications are helpful in reducing the challenges of memory, attention, mood and anxiety, as well as sleep and calmness. In many cases, psychotherapy for the patient can be useful, especially in the early stages. Psychoeducation, linkage to resources, and some psychotherapy shared with the family can also help provide a more fruitful home environment. We also integrate other modalities including supplements, cutting-edge neuromodulation, and holistic practices when they are evidence-based and desired by the family or patient.

Ready to get started? Schedule an intake appointment — a thorough evaluation where we clarify your diagnosis, map out your treatment plan, and get everything moving: medication orders, therapy, supplements, and nutrition. Your care begins the same day, not weeks later.

Schedule Your Intake

We offer statewide telehealth services in California and Florida, with in-person appointments available in Los Angeles and Miami. We also regularly assist international patients due to our fluency in Portuguese, Spanish, and Farsi.

---

📚 References

1. McKeith, I. G., Boeve, B. F., Dickson, D. W., et al. (2017). Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology, 89(1), 88–100.
2. Williams, S. S. (2016). The terrorist inside my husband’s brain. Neurology, 87(13), 1308–1311.
3. Iranzo, A., Tolosa, E., Gelpi, E., et al. (2013). Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. The Lancet Neurology, 12(5), 443–453.
4. Taylor, J. P., McKeith, I. G., Burn, D. J., et al. (2020). New evidence on the management of Lewy body dementia. The Lancet Neurology, 19(2), 157–169.
5. Outeiro, T. F., Koss, D. J., Erskine, D., et al. (2019). Dementia with Lewy bodies: an update and outlook. Molecular Neurodegeneration, 14(1), 5.
6. Aarsland, D., Ballard, C., Walker, Z., et al. (2009). Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. The Lancet Neurology, 8(7), 613–618.
7. Boot, B. P. (2015). Comprehensive treatment of dementia with Lewy bodies. Alzheimer’s Research & Therapy, 7(1), 45.
8. Mori, E., Ikeda, M., & Kosaka, K. (2012). Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Annals of Neurology, 72(1), 41–52.
9. Walker, Z., Possin, K. L., Boeve, B. F., & Aarsland, D. (2015). Lewy body dementias. The Lancet, 386(10004), 1683–1697.